You have successfully logged out.

menu
close

Medical Device Regulation

Information on the Medical Device Regulation

The new European Medical Device Regulation (MDR) with many new rules is a challenge for all involved. B. Braun is preparing intensely and wants to apply the new requirements as soon as possible. Here we have compiled some information about the MDR for you.

The new European Medical Device Regulation (MDR) went into force in May 2017. The new regulation replaces the existing Medical Device Directive (MDD) and the Active Implantable Medical Device Directive (AIMDD).    

 

In the future, the current approx. 500,000 medical devices in Europe will be recertified in accordance with the new, substantially more comprehensive policy to receive the CE mark. According to current estimates, approximately only 65 percent of the medical devices will be certified according to the new regulation. Some notified bodies are still in the accreditation phase and it is not fully clear as to how many notified bodies will be able to conclude the process (list on European Commission website). Due to the increased requirements placed on the notified bodies and the manufacturers, portfolio adjustments are expected and are inevitable. 

 

Implementation timeline of the MDR at B. Braun

The MDR entered into force on May 25, 2017. Here is an overview of implemetation related dates and periods. 
Image is temporarily not available.
close

May 2019 

May 2019 

Certification of B. Braun as manufacturer according to MDR 

close

May 25, 2021

May 25, 2021

Mandatory MDR application

close

May 26, 2024

May 26, 2024

Products must be MDR compliant when placed to the  market

close

May 26, 2025

May 26, 2025

End of all MDD transition periods

close

May 2021 – May 2024

May 2021 – May 2024

MDD certificate „grace period“: No design change for MDD certified  products

close

May 2024 - May 2025

May 2024 - May 2025

Sale of MDD certified  products

Which regulatory areas are affected?

Among others, these areas are affected:

  • Classification rules: The rules have been extended to include Class Ir (reusable surgically invasive instruments). The requirements related to implantable products of Class llb have increased. New risk classes have been introduced for several product categories, which potentially entails products being up-classified.
  • Clinical evidence: In the future, all medical devices are subject to a clinical evaluation obligation regardless of the class.
  • Scrutiny procedures (consultation procedure): New implantable Class III devices and Class llb active devices which administer and /or remove medicinals are to be more strictly controlled before market entry.
  • Notified bodies: The requirements placed on the notified bodies are increasing. At the same time, they will in the future be obliged to perform unannounced audits at manufacturers.
  • Technical documentation: Documentation due to the MDR increases significantly the effort for manufacturers.
  • EUDAMED: An electronic database for monitoring the product lifecycle has been introduced.

What kinds of challenges exist?

In order to be able to ensure continuous supply with safe and innovative medical technology, all manufacturers are faced with the challenging task of overcoming the increased requirements necessary to receive the CE mark. The notified bodies must lay the foundation and create sufficient capacity for the conformity assessment procedure. Currently it is unclear whether this can be realistically accomplished within the well-known given timeframe for the implementation of the MDR.

At an earlier point in time, B. Braun already began wide-ranging preparations for the certification of its own medical devices in accordance with the MDR.  Naturally, this applies to all products that B. Braun manufactures itself or purchases as commercial goods to complete its portfolio. With regard to the progress of the measures taken, B. Braun is confident it will be able to comply with the requirements of the MDR until May 2024, when all products must be MDR compliant.

General FAQs concerning the MDR

A revision of the Medical Device Directive 93/42 EEC (MDD), which was made public in 1993 and still applies today, became necessary at the European level. With the new regulation, EU authorities would like to improve the quality of medical devices and enhance safety, harmonize the processes through the EU, and increase patient safety. Additional aspects include the improvement of transparency and traceability in connection with new technologies that allow for the clear identification of all products throughout their entire lifecycle.  

The MDR defines the requirements that a manufacturer must meet in order to sell medical devices in Europe. Both the technical requirements for a product and the requirements placed on the monitoring of products used in healthcare facilities are affected.

There are several changes surrounding the classification of products. In addition to the introduction of the new class lr for reusable surgical instruments, the requirements placed on implantable products of class IIb have been especially increased. Furthermore, numerous product categories have been assigned to a higher risk class. The MDR increases the requirements pertaining to the clinical evidence of medical devices. In the future, all medical devices, regardless of their risk class, will require a clinical evaluation. The newly introduced scrutiny procedure means the improved monitoring of new, implantable products of risk class III, as well as active medical devices which administer and/or remove medicinals of Class IIb before market launch. In addition to the increased requirements placed on manufacturers, there are now stricter rules imposed on notified bodies. In order to be able to approve medical devices, various additional requirements must be met. Also, the notified bodies are obliged to perform unannounced audits at manufacturers. Additional requirements placed on the technical documentation that must be provided by manufacturers is substantially increasing the extent and complexity of the documentation. 

There is no exact identifier on the product to indicate MDR compliance. Nevertheless, a new ISO symbol “MD” for medical devices will be placed on the label along with the introduction of the MDR.

Yes, all medical devices of all risk classes, including the treatment units and systems, are affected. 

Data that is relevant for the public is made accessible in a central European database that already exists today. The expanded version of EUDAMED will be introduced stepwise, i.e. voluntary usage of a “minimal viable product” (MVP) version in 2022. Mandatory usage of the EUDAMED is expected to be in Q2 2025. See EUDAMED time line 
Legal manufacturers, system and procedure pack producers, importers, or authorized representatives for the distribution of medical devices in the EU must add to EUDAMED data pertaining to the role of the actor, as well as the product-relevant data for each individual product to be distributed in the EU. 

After the MDR was published on May 5th, 2017, the regulation went into force on May 25th, 2017, with a transition period that was intended to last until May 26th, 2020. Due to the COVID-19 pandemic the mandatory application of the MDR was postponed to May 2021. Until max. May 26th, 2024, MDD certificates will maintain their validity (e.g. for products of risk classes II and III), unless it is required that an MDD certificate is to be replaced by an MDR certificate (e.g. for products of risk class 1). After May 26th, 2025, products with an MDD certificate may no longer be placed on the market.

Due to the COVID-19 pandemic, the mandatory application for MDR was set for May 26th, 2021. This results in the following deadlines for the marketing of medical devices according to product classes:

Class I: May 26th, 2021

Class Ir, s, m, Class IIa, Class IIb and Class III:  May 26th, 2024

No, all products that were placed on the market before May 25th, 2021 can be distributed for an additional four years. Products which are put into service prior to May 2025 can remain in use by the end user as well.   

The conformity assessment says whether a product and the respective manufacturer complies with the European MDR requirements. Depending on the risk classification of the individual products, B. Braun is entitled to carry out this audit itself. The additional evaluations are carried out via a so-called “notified body”.

A notified body is a private company that is named on behalf of the European Union to evaluate the conformity of a manufacturer with the MDR. Currently they are being evaluated with audits and after they have passed the audits, the notified bodies will then evaluate the processes of medical device manufacturers for MDR conformity. As soon as the compliance of the processes has been verified, products that are processed can be registered through these processes.   

Even after converting the entire product portfolio to MDR, manufacturers will face significant additional costs due to the increased requirements of the MDR. 

The main objectives of the regulation are better protection of public health and patient safety, more transparency, legal security and a more European-oriented concept. This is to be achieved through more extensive technical documentation on the affected products in an MDR-compliant quality management system.

FAQs concerning the MDR & B. Braun

As a manufacturer of medical devices, B. Braun must comply with the requirements by May 2021. Different work groups are updating the technical documentation and revising processes in order to ensure they are MDR compliant. Furthermore, B. Braun is obliged to provide product information, including unique device identification data (UDI), as well as post market surveillance information to EUDAMED.  

The B. Braun Group has already initiated comprehensive measures and provided resources to ensure the on-schedule implementation of the MDR. 

All medical devices and ln-vitro diagnostics. Also, all products that are certified for the first time in accordance with the new Class Ir.

For some time, B. Braun has been preparing itself intensively for the new regulations and assumes it will be able to adhere to the timeline.

The quality management systems of B. Braun Melsungen AG, B. Braun Avitum AG and Aesculap AG have already been certified in accordance with the MDR and  MDR-compliant technical documentations for our products have already been prepared  . The product transfer to MDR will take place successively up to the maximum term in early 2024.

Generally speaking, yes – depending on the planned lifecycle, the products are certified according to MDR. As in previous years, B. Braun will continue to make adjustments to its product portfolio. New products will be added to the portfolio and older generations will be replaced, or uneconomical or outdated products will be removed from the product portfolio. As part of our regular assortment management process, we will continue to communicate corresponding product assortment changes in a timely, open, transparent and targeted manner to the respective customers affected and offer alternatives where possible.

 

B. Braun is using the MDR transition period in which we will transfer our product portfolio to MDR by May 2024 at the latest. During this transition period, B. Braun will place both MDD and MDR certified products on the market.

TÜV Süd was recognized as the second notified body worldwide in May 2019. Further notified bodies supervising medical devices of B. Braun are MedCert, Dekra and TÜV Rheinland which received their designation under MDR as well. Please check the link to the European Commission’s website to obtain an overview on MDR accredited notified bodies.   
European Commission’s website

a) The identification of a medical device will change through the inclusion of the unique device identification (UDI).

b) It is possible that extended documentation obligations arise through new Class III products.

c) The EUDAMED database provides customers more transparency with regard to products.

B. Braun is MDR-ready and has already made high investments in the multi-digit million range to achieve this. Major cost factors are more comprehensive requirements for the technical documentation, technical and systemic solutions to meet the required EUDAMED data management as well as increased post market surveillance efforts.  

B. Braun is actively supporting customers in obtaining information. To this end, Declarations of Conformity and Informations for Use (IFU) are made successively available digitally since May 2021.

 

Declarations of conformity can be found online at www.bbraun.com - simply by entering the product name in the search field and finding the corresponding Declaration of Conformity under the heading -related documents-. Most of the declarations of conformity of B. Braun Melsungen AG and B. Braun Avitum AG can be accessed via this channel. For technical reasons, B. Braun will only be able to make the declarations of conformity for Aesculap AG products (with the exception of the suture material portfolio) available online in the medium term. For the random provision of declarations of conformity, which cannot be found online, the known contacts from the customer service of the B. Braun national subsidiary can be approached.

 

Instructions for use can be downloaded at https://eifu.bbraun.com After entering the article number or the GTIN, the documents belonging to the product are displayed. 

Stay connected with My B. Braun

With your personalized account, your online experience will be easier, more comfortable and safe.

person_outline My B. Braun